

乳酸菌發酵豆漿之抗肥胖功效

2016.11.16

謝承哲 (5120)

大綱

一、前言

二、乳酸菌發酵豆漿產品的抗肥胖功效

三、以動物模式探討乳酸菌發酵豆漿對脂質代謝與腸道微生物群的影響

四、以動物模式探討乳酸菌發酵豆漿改善高血糖症、脂質分佈並增加抗氧化酶活性影響

五、結論

摘要

大豆富含豐富蛋白質與小分子胜肽，其胜肽具有降高血壓、抗氧化，抗肥胖、降血糖之功效，而乳酸菌則具有抑制腸道病原菌、降膽固醇等功效。本報告主要為探討以乳酸菌發酵豆漿之抗肥胖效果。以高脂飲食 (High-Fat Diet) 誘導肥胖之 Wistar 大鼠並分別給予 *Lactobacillus.paracasei* subsp.*paracasei* NTU 101 與 *L.plantarum* NTU 102 之發酵豆漿分別命名為 SM101 與 SM102 組，此兩組血清中的瘦體素 (Leptin) 皆有顯著提升，在 3T3-L1 細胞試驗中，此兩組別皆減少脂肪酸的攝取與累積，促進脂肪細胞縮小，其原因可能是 SM101 與 SM102 組將異黃酮轉換成木質素異黃酮 (Daidzein) 和金雀異黃酮 (Genistein)，顯示具有抗肥胖的功效。以 *L.plantarum* P-8 發酵之豆漿對高血脂大鼠的影響，相較於高脂飲食組 (M)，給予發酵豆漿組別之大鼠其血液中總膽固醇 (TC)、三酸甘油酯 (TG)、低密度脂蛋白膽固醇 (LDL - C)、ApoB/ApoA - I 指標、丙二醛含量分別降低 54%、47%、35%、44%、16%，而高密度脂蛋白膽固醇 (HDL - C)、總抗氧化能力 (T - AOC)、超氧化物歧化酶 (SOD)、麩胱甘肽過氧化物酶 (GSH - Px) 則提升 26%、50%、54%、12%，經由 H&E 染色觀察肝脂肪累積，發酵豆漿組有顯著抑制肝脂肪累積；在腸道微生物群中，*Lactobacillus*、*Bifidobacterium*、*Bacteroides*，分別提高 43%、9%、44%，*Clostridium* 群則下降 92%，結果顯示由 *L.plantarum* P-8 發酵豆漿抑制脂肪吸收且能藉由腸道微生物調節脂質代謝。此外評估 *L. CRL981* 發酵豆漿對鏈佐黴素 (Streptozotocin,STZ) 誘導糖尿病小鼠之影響，發現 STZ + SM981 組 (STZ 誘導並餵食 *L.CRL981* 發酵的豆漿) 相較 STZ 組，成長率、過氧化氫酶 (Catalase,CAT)、SOD、酵素活性提高 23%、50.5%、55.4%；血糖、糖化血色素值 (HbA1c)、LDL 值分別降低 40.2%、23.6%、20%；TC、TG 值分別降低 1.3 倍與 1.5 倍，其原因為 *L. CRL981* 具有高 β -glucosidase 活性能完全水解豆漿中異黃酮糖苷配基使其能被生物利用，達到改善高血糖症、脂質分佈並增加抗氧化酶活性。綜合以上所述，以乳酸菌發酵之豆漿具有良好的抗肥胖與改善高血糖的潛力。

參考資料

- 林榮耀 (2010)。脂肪酸的分解代謝。生物化學 (691 頁)。新北市：歐亞書局有限公司。
- 行政院衛生福利部。(2016) 臺灣肥胖的情形。<http://www.doh.gov.tw>，資料於 2016 年 11 月 6 日下載。
- 張立海、陳福軍、王嬌、史逸華、鐘敏。2012。肥胖的外科治療方法比較。Heilongjiang Medicine And Pharmacy。35(3) : 73
- 陳靠山、郭敏、吳少云、彭正華、徐譽泰。2006。一種發酵食品對動物體重和脂肪積累的降低效應。皖南醫學院學報。25(4) : 241-247
- Chen, S. T., Ferng, S. H., Yang, C. S., Peng, S. J., Lee, H. R., & Chen, J. R. (2005). Variable effects of soy protein on plasma lipids in hyperlipidemic and normolipidemic hemodialysis patients. *American Journal of Kidney Diseases*, 46(6): 1099-1106.
- Decaria J. E., Sharp C, Petrella RJ (2012) Scoping review report: obesity in older adults. *International Journal Obesity (Lond)*, 36:1141–1150.
- Kim, S. E., Kim, H. H., Kim, J. Y., Kang, Y. I., Woo, H. J., & Lee, H. J. (2000). Anticancer activity of hydrophobic peptides from soy proteins. *Biofactors*, 12(1-4): 151-155.
- Kodera, T., & Nio, N. (2002). Angiotensin converting enzyme inhibitors. PCT international applications WO, 2002055546, A1.
- Laurin, D., Jacques, H., Moorjani, S., Steinke, F. H., Gagne, C., Brun, D., & Lupien, P. J. (1991). Effects of a soy-protein beverage on plasma lipoproteins in children with familial hypercholesterolemia. *The American Journal of Clinical Nutrition*, 54(1): 98-103.
- Lee, B. H., Lo, Y. H., & Pan, T. M. (2013). Anti-obesity activity of *Lactobacillus* fermented soy milk products. *Journal of Functional Foods*, 5(2): 905-913.
- Mattan, K., Manthey, J. A., Luzio, G., Talcott, S. T., Goodner, K., Baldwin, E. A. (2006). Total antioxidant activity and fiber content of select Florida-grown tropical fruits. *Journal of Agricultural and Food Chemistry*, 54(19): 7355-7363.
- Marazza, J. A., Garro, M. S., & de Giori, G. S. (2009). Aglycone production by *Lactobacillus rhamnosus* CRL981 during soymilk fermentation. *Food Microbiology*, 26(3): 333-339.
- Marazza, J. A., Nazareno, M. A., de Giori, G. S., & Garro, M. S. (2012). Enhancement of the antioxidant capacity of soymilk by fermentation with *Lactobacillus rhamnosus*. *Journal of Functional Foods*, 4(3): 594-601.
- Marazza, J. A., LeBlanc, J. G., de Giori, G. S., & Garro, M. S. (2013). Soymilk fermented with *Lactobacillus rhamnosus* CRL981 ameliorates hyperglycemia, lipid profiles and increases antioxidant enzyme activities in diabetic mice. *Journal of Functional Foods*, 5(4): 1848-1853.

- Owen J, Reisin E (2012) Non-communicable disease: a welcome and long needed addition to the WHO's 2012 *World Health Statistics*, 14: 475–477.
- Sam, S., & Mazzone, T. (2014). Adipose tissue changes in obesity and the impact on metabolic function. *Translational Research*, 164(4): 284-292.
- Singh, B. P., Vij, S., & Hati, S. (2014). Functional significance of bioactive peptides derived from soybean. *Peptides*, 54: 171-179.
- Lee, J. S. (2006). Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. *Life Sciences*, 79(16): 1578-1584.
- Tsai, Y. T., Cheng, P. C., Fan, C. K., & Pan, T. M. (2008). Time-dependent persistence of enhanced immune response by a potential probiotic strain *Lactobacillus paracasei* subsp. *paracasei* NTU 101. *International Journal of Food Microbiology*, 128(2): 219-225.
- Tsai, Y. T., Cheng, P. C., & Pan, T. M. (2014). Anti-obesity effects of gut microbiota are associated with lactic acid bacteria. *Applied Microbiology and Biotechnology*, 98(1): 1-10.
- Wang, Z., Bao, Y., Zhang, Y., Zhang, J., Yao, G., Wang, S., & Zhang, H. (2013). Effect of soymilk fermented with *Lactobacillus plantarum* P-8 on lipid metabolism and fecal microbiota in experimental hyperlipidemic rats. *Food Biophysics*, 8(1): 43-49.
- Yoshikawa, M., Fujita, H., Matoba, N., Takenaka, Y., Yamamoto, T., Yamauchi, R., & Takahata, K. (2000). Bioactive peptides derived from food proteins preventing lifestyle-related diseases. *Biofactors*, 12(1-4): 143-146.